MARKET

ENSC

ENSC

Ensysce Biosciences Inc
NASDAQ
0.3872
+0.0271
+7.53%
Closed 18:38 11/12 EST
OPEN
0.3992
PREV CLOSE
0.3601
HIGH
0.4299
LOW
0.3800
VOLUME
391.35K
TURNOVER
--
52 WEEK HIGH
2.170
52 WEEK LOW
0.2300
MARKET CAP
7.53M
P/E (TTM)
-0.1407
1D
5D
1M
3M
1Y
5Y
1D
UBS Initiates Coverage of Ensysce Biosciences with Buy
NASDAQ · 8h ago
Ensysce Biosciences GAAP EPS of -$4.52 misses by $4.40
Seeking Alpha · 10h ago
Ensysce Biosciences Q3 Adj. EPS $(0.13) Misses $(0.12) Estimate, Sales $2.182M Beat $1.200M Estimate
Benzinga · 11h ago
Ensysce Biosciences Reports Third Quarter 2026 Financial Results and Business Highlights
Barchart · 17h ago
This Kimball Electronics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Benzinga · 18h ago
Ensysce Biosciences Price Target Announced at $2.00/Share by UBS
Dow Jones · 19h ago
UBS Initiates Coverage On Ensysce Biosciences with Buy Rating, Announces Price Target of $2
Benzinga · 20h ago
Ensysce Biosciences initiated with a Buy at UBS
TipRanks · 22h ago
More
About ENSC
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company. It develops solutions for severe pain relief while reducing the potential for opioid misuse, abuse, and overdose. Its pipeline includes an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection (TAAP) platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant (MPAR) platform. Its lead product, PF614, is a TAAP extended-release oxycodone and a potential analgesic to treat severe pain. Its second product, PF614-MPAR, is to treat severe pain with the added benefit of oral overdose protection, is a combination product of the TAAP prodrug PF614 with a trypsin inhibitor. Additionally, nafamostat, which is an ingredient in its overdose protection combination products, is also being developed for the intended purpose of treating infection and pulmonary lung diseases. It is also developing novel neuroplastogenic therapies for complex regional pain syndrome.

Webull offers Ensysce Biosciences Inc stock information, including NASDAQ: ENSC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ENSC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ENSC stock methods without spending real money on the virtual paper trading platform.